Search Bar & Filters
Found 5 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the safety and effectiveness of ELAPR002f injectable gel in adults with moderate to severe atrophic acne scars. These scars are flat or indented marks that remain after acne heals and can affect quality of life through reduced self-esteem and embarrassment. The study is a controlled, randomized trial including about 395 adults with scarring on both cheeks, conducted at multiple sites in the United States. Participants are divided into two cohorts. Cohort 1 receives ELAPR002f injectable gel openly, while Cohort 2 participants are randomly assigned to receive either ELAPR002f gel or a saline control via intradermal injections. Treatments are given on Days 1, 31, and 61. After the three treatment sessions over two months, participants are followed for up to 12 months to observe outcomes and any side effects. During the study, participants will have regular visits at a clinic or hospital for medical assessments, blood tests, and questionnaires to monitor their progress and any side effects. Researchers will measure the percentage of participants who achieve at least a 20% reduction in acne scar area and various safety parameters, including injection site responses and changes in vital signs and laboratory values. The total study duration for each participant can be up to 420 days.
Actively Recruiting
Researchers are collecting blood samples from adults who have cancer, are in cancer remission, have benign diseases such as diabetes or liver conditions, or are healthy volunteers. The study aims to evaluate specific DNA methylation markers in the blood to help detect various types of cancer and understand factors that may affect test results. Participants will provide whole blood, plasma, and serum samples that will be analyzed using a multi-analyte blood test designed to detect DNA methylation markers for cancer detection. The study will also investigate how benign conditions and substances like chemotherapy drugs might influence the tests accuracy. During the study, blood samples will be collected and examined to measure the tests sensitivity and specificity, check for interfering substances, and assess sample stability and reference ranges. Participants will be involved in providing blood samples within an 8-week period, and the main outcomes will be reviewed about one month after collection. The study is sponsored by Helio Genomics and is expected to complete in early 2028.
Actively Recruiting
Researchers are studying adolescents aged 12 to under 18 years with asthma who have had at least one severe asthma attack in the past year. This trial compares the effects of two inhalers a combination budesonidealbuterol inhaler and an albuterol-only inhaler, both used as needed. The goal is to see which inhaler better reduces severe asthma exacerbations over one year. Participants will be randomly assigned to use either the budesonidealbuterol inhaler or the albuterol inhaler as needed, in addition to their usual asthma maintenance therapy. The study lasts 52 weeks and includes a 7 to 28 day screening period before treatment and a safety follow-up period of 7 to 14 days after treatment ends. A separate pharmacokinetic sub-study involves a single visit after safety follow-up to evaluate drug levels after one dose of the budesonidealbuterol inhaler. During the study, participants will be regularly monitored for asthma attacks and medication use. Researchers will assess lung function, inhaler technique, and collect safety information including any adverse events. The main outcome is the annual rate of severe asthma exacerbations. Additional measures include time to first severe attack and corticosteroid use. Participants will complete peak flow measurements and have urine pregnancy tests if applicable. The total participation duration is approximately one year plus follow-up.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of combining gedatolisib with palbociclib and endocrine therapy compared to endocrine therapy with ribociclib for treating adults with locally advanced or metastatic hormone receptor-positive, HER2-negative breast cancer. This Phase 3, open-label, randomized clinical trial focuses on patients who are either endocrine-resistant or endocrine-sensitive based on their cancer progression and prior treatments. Participants will be assigned based on endocrine sensitivity status to one of two studies. Study 1 includes patients with endocrine-resistant cancer receiving either gedatolisib plus palbociclib and fulvestrant or ribociclib with fulvestrant. Study 2 includes endocrine-sensitive patients treated with gedatolisib plus palbociclib and letrozole or ribociclib plus letrozole. Gedatolisib is given intravenously once weekly for three weeks followed by a week off. Palbociclib and ribociclib are taken orally on days 1 to 21 of each 28-day cycle. Fulvestrant is administered by intramuscular injection every 2 to 4 weeks, while letrozole is taken orally daily. Throughout the study, participants undergo regular assessments including scans and laboratory tests to monitor disease progression and safety. Researchers measure outcomes such as progression-free survival, overall survival, response rates, duration and time to response, clinical benefits, quality of life, and adverse events over approximately 48 months. The trial includes screening to confirm eligibility and ongoing monitoring during and after treatment to evaluate the treatments effects and safety.
Actively Recruiting
Researchers are evaluating the Glide control strategy for upper limb prostheses in people with trans-radial unilateral limb loss. The study compares Glide, an experimental myoelectric control system using multiple EMG inputs, with the standard Direct Control DC prosthesis method. The goal is to assess whether Glide improves functional performance, satisfaction, and prosthesis usage over standard care in a clinical setting and during daily activities. Participants will use a single prosthesis system equipped to operate in both DC and Glide modes. The study follows a multiple baseline AB design over 24 weeks, where the A phase involves using the DC prosthesis for 10, 12, or 14 weeks, followed by the B phase using the Glide prosthesis for the remaining weeks. Prostheses are customized and fitted through multiple clinic visits, including occupational therapy training. Control modes are switched via an iPad app without hardware changes. Participants will attend several clinic visits for fitting, training, and assessments, completing questionnaires and functional tests such as CAPROQ, CAPPFUL, tBBT, FIT, DASH, and SAM at baseline, midpoints, crossover, and endpoint. Usage data like movement bouts and wear duration are recorded daily. The study includes weekly and periodic evaluations over the 24-week period, after which participants are refitted with their original prosthesis and receive further occupational therapy as needed.